They are divided into first-generation inhibitors, which target the PRMT5 protein but result in adverse side effects like anemia and thrombocytopenia, and second-generation inhibitors that target the PRMT5-MTA complex which do not cause any severe side effects [14]. Here, PRMT5 is linked to anemia.